Online inquiry

IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ5795MR)

This product GTTS-WQ5795MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Kidney transplant rejection, Psoriasis, Myasthenia Gravis (MG) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_001250.6
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	958
UniProt ID	P25942

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5795MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ6766MR	IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	DS-1062
GTTS-WQ3986MR	IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	BG9924
GTTS-WQ13965MR	IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	REGN3470-3471-3479
GTTS-WQ14819MR	IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	SGN-75
GTTS-WQ5876MR	IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	CIFN
GTTS-WQ3064MR	IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	Anti-TFPI
GTTS-WQ6445MR	IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	CT-P23
GTTS-WQ302MR	IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	19D12

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST